ependymoma/gin diare

Lyen an sove nan clipboard la

AtikEsè klinikPatant

Chwazi kalite sòt

10 rezilta yo

Thoracic spinal cord tumor presenting with dysautonomic diarrhea.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

A patient, presenting with incapacitating diarrhea of 1-month duration, developed orthostatic hypotension and progressive long tract central nervous system signs. No enteric disease was found to account for the diarrhea. An intramedullary midthoracic spinal cord tumor (ependymoma) was found.

Recurrent intracranial ependymoma in children: salvage therapy with oral etoposide.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Chronic oral VP-16 (etoposide) is a chemotherapy regimen with a wide application in oncology and documented efficacy against germ cell tumors, lymphomas, Kaposi's sarcoma, and primary brain tumors. This study was performed to assess the toxicity and activity of chronic oral etoposide in the

Phase I study of 5-fluorouracil in children and young adults with recurrent ependymoma.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND We report a phase I study to examine the pharmacokinetics, safety, and recommended dosage of weekly intravenous bolus 5-fluorouracil (5-FU) in children and young adults with recurrent ependymoma. METHODS Patients 22 years of age or less with recurrent ependymoma were treated with bolus

An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN).

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Co-expression of ERBB2 and ERBB4, reported in 75% of pediatric ependymomas, correlates with worse overall survival. Lapatinib, a selective ERBB1 and ERBB2 inhibitor has produced prolonged disease stabilization in patients with ependymoma in a phase I study. Bevacizumab exposure in ependymoma

Salvage chemotherapy for recurrent spinal cord ependymona.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Ependymomas are reported to constitute 4% of all primary central nervous system (CNS) malignancies in adults, 30% of which occur in the spinal cord. A prospective Phase II study to determine toxicity and response to chronic oral etoposide in patients with recurrent low-grade

Etoposide-containing regimens with autologous bone marrow transplantation in children with malignant brain tumors.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Despite improvements in neurosurgical and neuroradiotherapeutic techniques, children with malignant brain tumors have a dismal prognosis. In an attempt to improve the efficacy of cytotoxic therapy, dose intensification of effective chemotherapeutic agents followed by autologous bone marrow

March 2003: a 41 -year-old female with a solitary lesion in the liver.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The March COM. A 41-year-old woman presented in 1997 with diffuse abdominal pain, meteorism and intermittent diarrhea. Imaging studies revealed a focal rounded lesion in the liver. Although there was no history of progesterone or estrogen therapy, the radiographic appearance was considered to be

A phase I study of irinotecan administered on a weekly schedule in pediatric patients.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND The objectives of this study were to determine the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), pharmacokinetics, and anti-tumor effect of irinotecan in pediatric patients with recurrent or refractory malignancies. METHODS Twenty-three patients between 1 and 21 years of

Phase II study of daily oral etoposide in children with recurrent brain tumors and other solid tumors.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Pre-clinical data and adult experience suggests that topoisomerase targeted anti-cancer agents may be highly schedule dependent, and efficacy may improve with prolonged exposure. To investigate this hypothesis, 28 children with recurrent brain and solid tumors were enrolled in a phase II study of

A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND We conducted a phase 1 trial to determine the maximum tolerated dose (MTD), toxicity profile, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of cabozantinib in children with refractory or relapsed solid tumors. METHODS Patients received cabozantinib tablets on a

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye